Pirodavir, also known as R 77975, is a capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes. Pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold.